Home › Peripheral T-Cell Lymphoma › Texas
Peripheral T-Cell Lymphoma clinical trials in Texas
10 studies for Peripheral T-Cell Lymphoma are looking for participants at sites in Texas.
Cities in Texas
A Phase II, Single-center, Single-arm Study Evaluating the Safety and Efficacy of Golidocitinib in the Management of Newly Diagnosed Peripheral T Cell Lymphoma Patients (GOLDEN Study) and Correlative Study
- MD Anderson Cancer Center, Houston
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06630091Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma
- UT Southwestern Medical Center, Dallas
- MD Anderson Cancer Center, Houston
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06561048A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
- Md Anderson Cancer Center, Houston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 15, 2026 · NCT07195916AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.
- Research Site, Houston
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated Sep 14, 2026 · NCT06137144A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma
- The University of Texas - MD Anderson Cancer Center, Houston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 21, 2026 · NCT07192471Sample Collection for Ongoing Research and Product Evaluation Study - Non-Hodgkin Lymphoma (SCORE-NHL)
- Natera, Inc., Austin
RecruitingObservational study
Ages 18 and older · All sexes · Updated Aug 6, 2026 · NCT07750886To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL
- University of Texas, MD Anderson Cancer Center, Houston
- Baylor Scott & White Medical Center - Temple, Temple
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Jul 22, 2026 · NCT06072131Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas
- Houston Methodist Hospital, Houston
- Texas Children's Hospital, Houston
RecruitingPhase 1
Ages 12 to 75 · All sexes · Updated Jul 20, 2026 · NCT06176690Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
- Texas Children's Hospital, Houston
RecruitingObservational study
Ages 0 to 38 · All sexes · Updated Jun 4, 2026 · NCT06131801Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma
- The University of Texas MD Anderson Cancer Center, Houston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 22, 2025 · NCT04234048From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.